Rockville, MD (November 1, 2018) – Propagenix Inc., a privately-held biotechnology company focused on developing proprietary cellular technologies for regenerative medicine, has published a peer-reviewed article and been granted several US patents on its core technology for bioproduction of human epithelial stem cells, known as EpiX™ technology.

In an October 16, 2018 paper in Cell Reports (https://doi.org/10.1016/j.celrep.2018.09.072) entitled “Long-term in vitro expansion of epithelial stem cells enabled by pharmacological inhibition of PAK1-ROCK-Myosin II and TGF-β signaling”, Propagenix scientists describe compositions, methods, and mechanism to achieve trillion-fold or more expansion of human epithelial stem cells that are resident in many types of epithelial tissues including skin, airway, cornea, gastrointestinal tract and other barrier-type tissues. A central feature of this discovery is the absence for the need to use genetic elements, feeder cells or animal serum to achieve this level of cell expansion. This study also demonstrates preservation of genomic integrity and normal differentiative capacity of propagated epithelial stem cells using the EpiX technology. [Read more…]